Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx™/Doxil® in patients with hematological tumors

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 1, 2009, Pages 55-57

  Richly, Heike ^a   Grubert, M ^a   Scheulen, M E ^a   Hilger, Ralf A ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

Caelyx ; Doxil ; Liposomal doxorubicin; Pharmacokinetic

Indexed keywords

DOXORUBICIN; DOXORUBICINOL; LIPOSOME; MACROGOL; 7 DEOXY 13 DIHYDROADRIAMYCINONE; 7-DEOXY-13-DIHYDROADRIAMYCINONE; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE;

AREA UNDER THE CURVE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EXCRETION; DRUG HALF LIFE; DRUG UPTAKE; DRUG URINE LEVEL; ENCAPSULATION; HEMATOLOGIC MALIGNANCY; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTIPLE CYCLE TREATMENT; TREATMENT DURATION; ARTICLE; BLOOD; BLOOD DISEASE; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; DRUG MONITORING; EVALUATION; HALF LIFE TIME; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; METABOLISM;

ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; CLINICAL TRIALS AS TOPIC; DOXORUBICIN; DRUG MONITORING; HALF-LIFE; HEMATOLOGIC NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTES; SEVERITY OF ILLNESS INDEX;

EID: 65349163279     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47055     Document Type: Conference Paper

References (6)

1. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990; 33: 86-89.
2. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984; 310: 1353-1356.
3. Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, Marme D, Unger C. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res. 2004; 24: 1759-1763.
4. Hilger RA, Richly H, Grubert M, Oberhoff C, Strumberg D, Scheulen ME, Seeber S. Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil. Int J Clin Pharmacol Ther. 2005; 43: 588-589.
5. Twelves CJ, Dobbs NA, Aldhous M, Harper PG, Rubens RD, Richards MA. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer. Cancer Chemother Pharmacol. 1991; 28: 302-307.
6. Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA, Working PK. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol. 2004; 31 (6 Suppl 13): 16-35.